Recurrence of Chronic Urticaria: Incidence and Associated Factors

Julie K. Kim, Daniel Har, L. Steven Brown, David A. Khan

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Chronic urticaria (CU) is urticaria that has been present continuously or intermittently for at least 6 weeks. Although the prevalence and characteristics of CU are well established, little is known about recurrent CU (RCU). Objectives: We sought to establish a definition, determine the frequency, and evaluate risk factors for RCU. Methods: A retrospective chart review of adult patients with CU evaluated at the University of Texas Southwestern allergy and immunology clinic was performed. RCU was defined as CU recurring at least 6 months after cessation of controller therapy and resolution of prior CU symptoms. Charts were reviewed for symptom resolution and recurrence, subtypes of CU (idiopathic, physical, and urticarial vasculitis), and medication usage (first-line agents, alternative agents, and steroid dependence). Results: Forty-five of 341 patients (13%) had RCU. The recurrence group had a higher frequency of alternative agent use at 57.8% (n = 26) compared with the nonrecurrence group at 34.8% (n = 103), which was statistically significant (P < .01). The rate of steroid dependence was similar in both groups (13.3% in the recurrence group vs 14.5%) and not statistically significant. Individuals exposed to anti-inflammatory agents, immunosuppressants, and omalizumab had a significantly higher relative risk of recurrence compared with those who only used first-line agents (relative risk [RR] 2.32, P < .01; RR 2.69, P < .01; and RR 2.18, P = .05, respectively). Conclusions: RCU occurs in approximately 13% of patients with CU in our clinic population. Alternative agent use and antihistamine refractoriness appear to place patients at increased risk for recurrence compared with first-line agent use alone.

Original languageEnglish (US)
JournalJournal of Allergy and Clinical Immunology: In Practice
DOIs
StateAccepted/In press - 2017

Fingerprint

Urticaria
Recurrence
Incidence
Steroids
Histamine Antagonists
Immunosuppressive Agents
Vasculitis
Allergy and Immunology
Anti-Inflammatory Agents

Keywords

  • Chronic idiopathic urticaria
  • Chronic urticaria
  • Physical urticaria
  • Recurrent chronic urticaria
  • Urticarial vasculitis

ASJC Scopus subject areas

  • Immunology and Allergy

Cite this

Recurrence of Chronic Urticaria : Incidence and Associated Factors. / Kim, Julie K.; Har, Daniel; Brown, L. Steven; Khan, David A.

In: Journal of Allergy and Clinical Immunology: In Practice, 2017.

Research output: Contribution to journalArticle

@article{59bcb52732f8441da1a21a285025b366,
title = "Recurrence of Chronic Urticaria: Incidence and Associated Factors",
abstract = "Background: Chronic urticaria (CU) is urticaria that has been present continuously or intermittently for at least 6 weeks. Although the prevalence and characteristics of CU are well established, little is known about recurrent CU (RCU). Objectives: We sought to establish a definition, determine the frequency, and evaluate risk factors for RCU. Methods: A retrospective chart review of adult patients with CU evaluated at the University of Texas Southwestern allergy and immunology clinic was performed. RCU was defined as CU recurring at least 6 months after cessation of controller therapy and resolution of prior CU symptoms. Charts were reviewed for symptom resolution and recurrence, subtypes of CU (idiopathic, physical, and urticarial vasculitis), and medication usage (first-line agents, alternative agents, and steroid dependence). Results: Forty-five of 341 patients (13{\%}) had RCU. The recurrence group had a higher frequency of alternative agent use at 57.8{\%} (n = 26) compared with the nonrecurrence group at 34.8{\%} (n = 103), which was statistically significant (P < .01). The rate of steroid dependence was similar in both groups (13.3{\%} in the recurrence group vs 14.5{\%}) and not statistically significant. Individuals exposed to anti-inflammatory agents, immunosuppressants, and omalizumab had a significantly higher relative risk of recurrence compared with those who only used first-line agents (relative risk [RR] 2.32, P < .01; RR 2.69, P < .01; and RR 2.18, P = .05, respectively). Conclusions: RCU occurs in approximately 13{\%} of patients with CU in our clinic population. Alternative agent use and antihistamine refractoriness appear to place patients at increased risk for recurrence compared with first-line agent use alone.",
keywords = "Chronic idiopathic urticaria, Chronic urticaria, Physical urticaria, Recurrent chronic urticaria, Urticarial vasculitis",
author = "Kim, {Julie K.} and Daniel Har and Brown, {L. Steven} and Khan, {David A.}",
year = "2017",
doi = "10.1016/j.jaip.2017.07.012",
language = "English (US)",
journal = "Journal of Allergy and Clinical Immunology: In Practice",
issn = "2213-2198",
publisher = "Elsevier",

}

TY - JOUR

T1 - Recurrence of Chronic Urticaria

T2 - Incidence and Associated Factors

AU - Kim, Julie K.

AU - Har, Daniel

AU - Brown, L. Steven

AU - Khan, David A.

PY - 2017

Y1 - 2017

N2 - Background: Chronic urticaria (CU) is urticaria that has been present continuously or intermittently for at least 6 weeks. Although the prevalence and characteristics of CU are well established, little is known about recurrent CU (RCU). Objectives: We sought to establish a definition, determine the frequency, and evaluate risk factors for RCU. Methods: A retrospective chart review of adult patients with CU evaluated at the University of Texas Southwestern allergy and immunology clinic was performed. RCU was defined as CU recurring at least 6 months after cessation of controller therapy and resolution of prior CU symptoms. Charts were reviewed for symptom resolution and recurrence, subtypes of CU (idiopathic, physical, and urticarial vasculitis), and medication usage (first-line agents, alternative agents, and steroid dependence). Results: Forty-five of 341 patients (13%) had RCU. The recurrence group had a higher frequency of alternative agent use at 57.8% (n = 26) compared with the nonrecurrence group at 34.8% (n = 103), which was statistically significant (P < .01). The rate of steroid dependence was similar in both groups (13.3% in the recurrence group vs 14.5%) and not statistically significant. Individuals exposed to anti-inflammatory agents, immunosuppressants, and omalizumab had a significantly higher relative risk of recurrence compared with those who only used first-line agents (relative risk [RR] 2.32, P < .01; RR 2.69, P < .01; and RR 2.18, P = .05, respectively). Conclusions: RCU occurs in approximately 13% of patients with CU in our clinic population. Alternative agent use and antihistamine refractoriness appear to place patients at increased risk for recurrence compared with first-line agent use alone.

AB - Background: Chronic urticaria (CU) is urticaria that has been present continuously or intermittently for at least 6 weeks. Although the prevalence and characteristics of CU are well established, little is known about recurrent CU (RCU). Objectives: We sought to establish a definition, determine the frequency, and evaluate risk factors for RCU. Methods: A retrospective chart review of adult patients with CU evaluated at the University of Texas Southwestern allergy and immunology clinic was performed. RCU was defined as CU recurring at least 6 months after cessation of controller therapy and resolution of prior CU symptoms. Charts were reviewed for symptom resolution and recurrence, subtypes of CU (idiopathic, physical, and urticarial vasculitis), and medication usage (first-line agents, alternative agents, and steroid dependence). Results: Forty-five of 341 patients (13%) had RCU. The recurrence group had a higher frequency of alternative agent use at 57.8% (n = 26) compared with the nonrecurrence group at 34.8% (n = 103), which was statistically significant (P < .01). The rate of steroid dependence was similar in both groups (13.3% in the recurrence group vs 14.5%) and not statistically significant. Individuals exposed to anti-inflammatory agents, immunosuppressants, and omalizumab had a significantly higher relative risk of recurrence compared with those who only used first-line agents (relative risk [RR] 2.32, P < .01; RR 2.69, P < .01; and RR 2.18, P = .05, respectively). Conclusions: RCU occurs in approximately 13% of patients with CU in our clinic population. Alternative agent use and antihistamine refractoriness appear to place patients at increased risk for recurrence compared with first-line agent use alone.

KW - Chronic idiopathic urticaria

KW - Chronic urticaria

KW - Physical urticaria

KW - Recurrent chronic urticaria

KW - Urticarial vasculitis

UR - http://www.scopus.com/inward/record.url?scp=85028752696&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028752696&partnerID=8YFLogxK

U2 - 10.1016/j.jaip.2017.07.012

DO - 10.1016/j.jaip.2017.07.012

M3 - Article

C2 - 28888844

AN - SCOPUS:85028752696

JO - Journal of Allergy and Clinical Immunology: In Practice

JF - Journal of Allergy and Clinical Immunology: In Practice

SN - 2213-2198

ER -